In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailCompass Point's Max Reale talks the impact of a possible FDA ban on compounded GLP-1 offeringsMax Reale, Compass Point head of policy research, joins 'Closing Bell Overtime' to talk the current state of the weight-loss drug space and the impact of a possible compounded GLP-1 ban.

---

Persons: Max Reale Organizations: FDA